A novel compound exhibits potent anti-Candida albicans activity

Candida albicans is a prevalent fungal pathogen in humans worldwide, causing life-threatening invasive candidiasis in immunocompromised individuals, largely due to the scarcity and poor efficacy of present antifungals, necessitating the search for novel antifungal medications.By leveraging machine learning methodologies, we have identified a novel compound that demonstrates robust antifungal activity against C. albicans. To explore the mechanisms behind its efficacy, we undertook an extensive study involving transcriptomic profiling of C. albicansexposed to the compound across different cultivation times and doses.The findings of this study not only contribute to our understanding of antifungal mechanisms, but also have great potential to guide the development of innovative therapies against C. albicans for meeting the growing clinical demand for new treatments. Overall design: A comprehensive analysis of the transcriptome of C. albicans exposed to the compound under varying conditions of exposure time and concentration.